BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

  November 10, 2025

   · 

  4 min read
• Press Releases

  Wave Life Sciences to Present at Upcoming November 2025 Investor Conferences

  November 10, 2025

   · 

  2 min read
• Press Releases

  Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th

  November 10, 2025

   · 

  4 min read
• Press Releases

  New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

  November 10, 2025

   · 

  7 min read
• Press Releases

  Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine

  November 10, 2025

   · 

  5 min read
• Press Releases

  Gilead Provides Update on Phase 3 ASCENT-07 Study

  November 10, 2025

   · 

  16 min read
• Press Releases

  Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

  November 10, 2025

   · 

  11 min read
• Press Releases

  Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

  November 10, 2025

   · 

  14 min read
• Press Releases

  Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025

  November 10, 2025

   · 

  3 min read
• Press Releases

  IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

  November 10, 2025

   · 

  6 min read